L de Ridder
Overview
Explore the profile of L de Ridder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
1680
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goetgebuer R, van der Woude C, Bakker L, van der Eijk A, de Ridder L, de Vries A
Scand J Gastroenterol
. 2022 Jun;
57(11):1321-1326.
PMID: 35771203
Background: Clinical guidelines on cytomegalovirus (CMV) colitis in inflammatory bowel disease (IBD) are hampered by the low quality of evidence. In this study, we aim to explore the attitude and...
2.
Kucharzik T, Ellul P, Greuter T, Rahier J, Verstockt B, Abreu C, et al.
J Crohns Colitis
. 2021 Mar;
15(6):879-913.
PMID: 33730753
No abstract available.
3.
Veenbergen S, Li P, Raatgeep H, Lindenbergh-Kortleve D, Simons-Oosterhuis Y, Farrel A, et al.
Mucosal Immunol
. 2019 Aug;
12(5):1201-1211.
PMID: 31417161
Uncontrolled interferon γ (IFNγ)-mediated T-cell responses to commensal microbiota are a driver of inflammatory bowel disease (IBD). Interleukin-10 (IL-10) is crucial for controlling these T-cell responses, but the precise mechanism...
4.
Goetgebuer R, van der Woude C, de Ridder L, Doukas M, de Vries A
Int J Colorectal Dis
. 2019 Feb;
34(5):923-926.
PMID: 30739187
Background And Aim: Epstein-Barr virus (EBV) is a proposed trigger in the etiopathogenesis of inflammatory bowel disease (IBD) and is associated with lymphoproliferative diseases. Nevertheless, testing for EBV DNA in...
5.
Joosse M, Aardoom M, Kemos P, Turner D, WILSON D, Koletzko S, et al.
Aliment Pharmacol Ther
. 2018 Jul;
48(5):523-537.
PMID: 29984520
Background: Risk benefit strategies in managing inflammatory bowel diseases (IBD) are dependent upon understanding the risks of uncontrolled inflammation vs those of treatments. Malignancy and mortality in IBD have been...
6.
Cozijnsen M, Samsom J, de Ridder L
Paediatr Drugs
. 2017 Oct;
20(1):19-28.
PMID: 29079905
Antibodies directed to tumour necrosis factor-α (TNF-α) are very effective in treating paediatric Crohn's disease (CD). Over the last few years, research has provided important new insights into how to...
7.
Cozijnsen M, van Pieterson M, Samsom J, Escher J, de Ridder L
BMJ Open Gastroenterol
. 2017 Jan;
3(1):e000123.
PMID: 28090335
Introduction: Crohn's disease (CD) is a chronic inflammatory disease predominantly affecting the gastrointestinal tract. CD usually requires lifelong medication and is accompanied by severe complications, such as fistulae and strictures,...
8.
van den Brink G, van der Woude C, de Ridder L, van Gaalen M, Escher J
Ned Tijdschr Geneeskd
. 2016 Sep;
160:D578.
PMID: 27581867
The transfer of adolescent patients with inflammatory bowel disease (IBD) to adult gastroenterology services is often troublesome. Failed transition can have adverse effects on the course of disease. We present...
9.
de Ridder L, Maes D, Dewulf J, Butaye P, Pasmans F, Boyen F, et al.
Vet J
. 2014 Oct;
202(2):303-8.
PMID: 25278382
Salmonella enterica infection in pigs is economically important and poses a zoonotic risk. In this study, the efficacy of an attenuated S. enterica serovar Typhimurium strain was evaluated in three...
10.
Ruemmele F, Veres G, Kolho K, Griffiths A, Levine A, Escher J, et al.
J Crohns Colitis
. 2014 Jun;
8(10):1179-207.
PMID: 24909831
Children and adolescents with Crohn's disease (CD) present often with a more complicated disease course compared to adult patients. In addition, the potential impact of CD on growth, pubertal and...